Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme

Andrea Gori, Manuela Doroana, Oksana Chernova, Jürgen K. Rockstroh, D. Bánhegyi, Colm Bergin, Gabriella Verucchi, Chris Liu, Ralph DeMasi, Blanca Hadacek, Mark Nelson

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: HPC3005 is a multicentre, open-label, telaprevir trial in HCV/HIV coinfected patients with severe fibrosis or compensated cirrhosis. Methods: Patients were treated with telaprevir 750 mg every 8 h (1125 mg if on efavirenz) plus pegylated interferon-alpha (PEG-IFN, 180 μg once-weekly) and ribavirin (RBV, 800 mg/day) for 12 weeks, followed by 36 weeks of PEG-IFN/RBV. Results: Mean age was 44 years, 97/118 patients were male and all were Caucasian, 68 had severe fibrosis and 50 had cirrhosis. Seventy-eight had HCV RNA levels ≥800 000 IU/mL, 72 had HCV genotype 1a, baseline HIV RNA was

Original languageEnglish
Pages (from-to)675-682
Number of pages8
JournalJournal of Infection
Volume71
Issue number6
DOIs
Publication statusPublished - Dec 1 2015

Fingerprint

Hepacivirus
HIV-1
Fibrosis
efavirenz
HIV
RNA
Ribavirin
Therapeutics
Interferon-alpha
Genotype
telaprevir

Keywords

  • Bridging fibrosis
  • Cirrhosis
  • Coinfection
  • Hepatitis C
  • HIV
  • Telaprevir

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients : An early access programme. / Gori, Andrea; Doroana, Manuela; Chernova, Oksana; Rockstroh, Jürgen K.; Bánhegyi, D.; Bergin, Colm; Verucchi, Gabriella; Liu, Chris; DeMasi, Ralph; Hadacek, Blanca; Nelson, Mark.

In: Journal of Infection, Vol. 71, No. 6, 01.12.2015, p. 675-682.

Research output: Contribution to journalArticle

Gori, A, Doroana, M, Chernova, O, Rockstroh, JK, Bánhegyi, D, Bergin, C, Verucchi, G, Liu, C, DeMasi, R, Hadacek, B & Nelson, M 2015, 'Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme', Journal of Infection, vol. 71, no. 6, pp. 675-682. https://doi.org/10.1016/j.jinf.2015.09.013
Gori, Andrea ; Doroana, Manuela ; Chernova, Oksana ; Rockstroh, Jürgen K. ; Bánhegyi, D. ; Bergin, Colm ; Verucchi, Gabriella ; Liu, Chris ; DeMasi, Ralph ; Hadacek, Blanca ; Nelson, Mark. / Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients : An early access programme. In: Journal of Infection. 2015 ; Vol. 71, No. 6. pp. 675-682.
@article{58f33976ded541eeb21b568ed9d43d7b,
title = "Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme",
abstract = "Objectives: HPC3005 is a multicentre, open-label, telaprevir trial in HCV/HIV coinfected patients with severe fibrosis or compensated cirrhosis. Methods: Patients were treated with telaprevir 750 mg every 8 h (1125 mg if on efavirenz) plus pegylated interferon-alpha (PEG-IFN, 180 μg once-weekly) and ribavirin (RBV, 800 mg/day) for 12 weeks, followed by 36 weeks of PEG-IFN/RBV. Results: Mean age was 44 years, 97/118 patients were male and all were Caucasian, 68 had severe fibrosis and 50 had cirrhosis. Seventy-eight had HCV RNA levels ≥800 000 IU/mL, 72 had HCV genotype 1a, baseline HIV RNA was",
keywords = "Bridging fibrosis, Cirrhosis, Coinfection, Hepatitis C, HIV, Telaprevir",
author = "Andrea Gori and Manuela Doroana and Oksana Chernova and Rockstroh, {J{\"u}rgen K.} and D. B{\'a}nhegyi and Colm Bergin and Gabriella Verucchi and Chris Liu and Ralph DeMasi and Blanca Hadacek and Mark Nelson",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.jinf.2015.09.013",
language = "English",
volume = "71",
pages = "675--682",
journal = "Journal of Infection",
issn = "0163-4453",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients

T2 - An early access programme

AU - Gori, Andrea

AU - Doroana, Manuela

AU - Chernova, Oksana

AU - Rockstroh, Jürgen K.

AU - Bánhegyi, D.

AU - Bergin, Colm

AU - Verucchi, Gabriella

AU - Liu, Chris

AU - DeMasi, Ralph

AU - Hadacek, Blanca

AU - Nelson, Mark

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Objectives: HPC3005 is a multicentre, open-label, telaprevir trial in HCV/HIV coinfected patients with severe fibrosis or compensated cirrhosis. Methods: Patients were treated with telaprevir 750 mg every 8 h (1125 mg if on efavirenz) plus pegylated interferon-alpha (PEG-IFN, 180 μg once-weekly) and ribavirin (RBV, 800 mg/day) for 12 weeks, followed by 36 weeks of PEG-IFN/RBV. Results: Mean age was 44 years, 97/118 patients were male and all were Caucasian, 68 had severe fibrosis and 50 had cirrhosis. Seventy-eight had HCV RNA levels ≥800 000 IU/mL, 72 had HCV genotype 1a, baseline HIV RNA was

AB - Objectives: HPC3005 is a multicentre, open-label, telaprevir trial in HCV/HIV coinfected patients with severe fibrosis or compensated cirrhosis. Methods: Patients were treated with telaprevir 750 mg every 8 h (1125 mg if on efavirenz) plus pegylated interferon-alpha (PEG-IFN, 180 μg once-weekly) and ribavirin (RBV, 800 mg/day) for 12 weeks, followed by 36 weeks of PEG-IFN/RBV. Results: Mean age was 44 years, 97/118 patients were male and all were Caucasian, 68 had severe fibrosis and 50 had cirrhosis. Seventy-eight had HCV RNA levels ≥800 000 IU/mL, 72 had HCV genotype 1a, baseline HIV RNA was

KW - Bridging fibrosis

KW - Cirrhosis

KW - Coinfection

KW - Hepatitis C

KW - HIV

KW - Telaprevir

UR - http://www.scopus.com/inward/record.url?scp=84947591770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947591770&partnerID=8YFLogxK

U2 - 10.1016/j.jinf.2015.09.013

DO - 10.1016/j.jinf.2015.09.013

M3 - Article

C2 - 26416471

AN - SCOPUS:84947591770

VL - 71

SP - 675

EP - 682

JO - Journal of Infection

JF - Journal of Infection

SN - 0163-4453

IS - 6

ER -